CACNA1H
Voltage-dependent T-type calcium channel subunit alpha-1H
As of the edition of 20 October 2026, CACNA1H (voltage-dependent T-type calcium channel subunit alpha-1H, UniProt O95180) has 11 drugs tested at it and 7 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O95180
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Nervous system; Cancer; Mental health; Digestive system; Hormones; Bones, joints and muscles
- Registered trials of its drugs
- 41
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Went quiet | 1 |
| Stopped | 2 |
| Withdrawn from market | 1 |
| Status not established | 1 |
| Total | 11 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Flunarizine | Marketed | Phase 4 | none listed |
| Ethosuximide | Marketed | Phase 3 | none listed |
| Suvecaltamide | Stopped | Phase 2 | none listed |
| Apinocaltamide | Stopped | Phase 2 | none listed |
| Mibefradil | Withdrawn from market | Phase 1 | none listed |
| ABT-639 | Went quiet | Phase 2 | none listed |
| YHD1119 | Status not established | Phase 1 | none listed |
| Methsuximide | Marketed | No phase stated | none listed |
| Paramethadione | Marketed | No phase stated | none listed |
| Phensuximide | Marketed | No phase stated | none listed |
| Trimethadione | Marketed | No phase stated | none listed |
11 of 11 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Engaged | 1 |
| Undetermined | 4 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Neurocrine | Route A |
| AbbVie | Route A |
The other 5 companies at CACNA1H
In the product7 companies in all; 5 are not named here, and no score is.
See the 7 companies at CACNA1H, ranked, with the facts behind eachRequest access. Nothing is shown until you do.